Anthem (NASDAQ:ANTX) Issues Quarterly Earnings Results

Anthem (NASDAQ:ANTX) posted its quarterly earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, FiscalAI reports.

Anthem Price Performance

NASDAQ:ANTX opened at $4.00 on Monday. Anthem has a fifty-two week low of $1.00 and a fifty-two week high of $7.19. The stock has a market cap of $150.94 million, a PE ratio of -3.74 and a beta of -0.93. The firm’s fifty day simple moving average is $4.74 and its 200-day simple moving average is $4.11.

Insider Activity at Anthem

In related news, Director Robin Shane Readnour sold 10,019 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $6.02, for a total value of $60,314.38. Following the completion of the sale, the director owned 557,990 shares in the company, valued at $3,359,099.80. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 55,727 shares of company stock valued at $330,207 in the last ninety days. 22.61% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Vivo Capital LLC purchased a new position in Anthem in the 1st quarter valued at approximately $10,785,000. Commodore Capital LP purchased a new stake in Anthem during the first quarter worth $7,981,000. Spruce Street Capital LP purchased a new stake in Anthem during the first quarter worth $5,576,000. Ally Bridge Group NY LLC purchased a new stake in Anthem during the first quarter worth $1,800,000. Finally, Bank of America Corp DE boosted its position in Anthem by 2.2% during the first quarter. Bank of America Corp DE now owns 393,702 shares of the company’s stock worth $1,346,000 after purchasing an additional 8,390 shares in the last quarter. 90.47% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ANTX has been the topic of a number of analyst reports. Guggenheim assumed coverage on Anthem in a report on Monday, July 20th. They issued a “buy” rating and a $9.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Anthem in a research note on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Anthem has an average rating of “Hold” and an average price target of $9.00.

Anthem Company Profile

An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.